HIVSSSA: Evaluation of Secondary Distribution of HIV Self-screening Tests by Women With HIV

Sponsor
University of California, Los Angeles (Other)
Overall Status
Completed
CT.gov ID
NCT05074251
Collaborator
Emory University (Other), BroadReach Healthcare (Other), USAID, South Africa (Other), South African Department of Health, Mpumalanga Province (Other)
180
1
2
4.1
43.5

Study Details

Study Description

Brief Summary

Many South African men do not visit clinics or get tested due to multiple real and perceived barriers. Nkangala District has significant gaps to identifying PLHIV who are not on ART, reaching their ART targets, especially in adult men. Over 65% of PLHIV not on ART are men, which is a gap of over 39,000 men living with HIV needing to be tested and initiated on ART.

  • To improve case finding among men in Nkangala we will evaluate how best to reach partners of PLHIV (newly diagnosed or on ART) with index testing by using HIV self-screening (HIVSS) and linkage to ART start.

  • Secondary distribution of HIV self-screening kits (HIVSS), whereby clients bring HIVSS kits to their partners, addresses barriers by enabling partners to screen themselves at their convenience and in the privacy of their homes.

Study Objectives: BroadReach in collaboration with UCLA, UCT and Nkangala DOH will pilot test an innovative index partner HIVSS strategy in one urban and one rural clinic to evaluate acceptability, barriers, and efficacy of secondary HIVSS distribution in a randomized control trial enrolling women newly diagnosed with HIV or on ART.

  • In the intervention arm, women will receive counselling on how to use HIVSS, how to encourage their male partner to screen, and 2 oraquick HIVSS with instructions and invitation to return for confirmatory testing.

  • In the standard of care arm, index women will receive counselling on the importance of disclosure to their family and partner(s) and referral for HIV testing (per South African national guidelines).

Study design: Randomized control trial of n=180 WLHIV (90 in each arm) in four facilities (urban and rural) in the Nkangala district ensure that the results are generalizable.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: HIV self test
  • Behavioral: Counseling and referral for partner testing
N/A

Detailed Description

Many South African men do not visit clinics or get tested due to multiple real and perceived barriers. Nkangala District has significant gaps to identifying PLHIV who are not on ART, reaching their ART targets, especially in adult men. Over 65% of PLHIV not on ART are men, which is a gap of over 39,000 men living with HIV needing to be tested and initiated on ART.

  • To improve case finding among men in Nkangala we will evaluate how best to reach partners of PLHIV (newly diagnosed or on ART) with index testing by using HIV self-screening (HIVSS) and linkage to ART start.

  • Secondary distribution of HIV self-screening kits (HIVSS), whereby clients bring HIVSS kits to their partners, addresses barriers by enabling partners to screen themselves at their convenience and in the privacy of their homes.

We will partner with BroadReach Healthcare, a PEPFAR partner in South Africa, to pilot test an innovative index partner HIVSS strategy in one urban and one rural public health clinic in the Nkangala district of Mpumalanga Province to evaluate acceptability, barriers, and preliminary efficacy of secondary HIVSS distribution in a randomized control trial enrolling women newly diagnosed with HIV or on ART. In the intervention arm, women will receive counselling on how to use HIVSS, how to encourage their male partner to screen, and 2 HIVSSs with HIVSS instructions and invitation to return for confirmatory testing. In the standard of care arm, index women will receive counselling on the importance of disclosure to their family and partner(s) and referral for HIV testing (per SA national guidelines). We will evaluate the following aims:

  1. Conduct a mixed-methods survey with N=180 HIV+ women to assess perceived acceptability and barriers (including perceived safety, IPV) to secondary HIVSS distribution by women to male partners.

  2. Test the feasibility and preliminary efficacy of secondary HIVSS distribution through a 1:1 randomized control trial in n=180 HIV+ women to assess, comparing standard of care to intervention arm:

  3. % of index women who self-report that they gave the HIVSS or standard of care referral for testing to their male partner

  4. % of male partners who either screened or tested for HIV assessed at 3 months after randomization (primary outcome)

  1. Measured via options of: index or partner self-report, SMS/WhatsApp of a picture of the used HIVSS sent by partner or index, return of a used self-test to the facility by either the index or partner, and/or partner coming into facility for with an invitation for confirmatory testing or SOC counseling referral c. % of male partners with a positive HIV screening/test result d. % of newly diagnosed male partners who initiate ART within 3 months of diagnosis e. % of those on ART with viral suppression after 6 months on ART (index and partners)
  1. In the intervention arm, we will assess acceptability and barriers (including safety/IPV) related to HIVSS distribution or use via surveys with all intervention participants who return for the study endline survey and a convenience samples of n=20 male partners (n=10 men who used HIVSS and n=10 men who did not use HIVSS)

Study Design

Study Type:
Interventional
Actual Enrollment :
180 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Pilot Study of Secondary Distribution of HIV Self-screening Tests by Women With HIV: An Innovative Strategy to Improve Testing, Identification, and Linkage to Treatment of Men in South Africa
Actual Study Start Date :
Apr 20, 2021
Actual Primary Completion Date :
Aug 6, 2021
Actual Study Completion Date :
Aug 24, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: HIV self testing

HIV+ women will receive HIV self-tests (2) to bring home to her partner to offer for testing

Diagnostic Test: HIV self test
For women allocated to the intervention arm, the participant will be given HIV self testing and counseling on their use & importance of partner testing, to take home to their partner(s).
Other Names:
  • counseling on partner testing and HIV self testing
  • Behavioral: Counseling and referral for partner testing
    Counseling and refer participant's partner for facility based HIV testing

    Active Comparator: Standard of care

    In the standard of care arm, women will receive standard of care partner referrals for HIV testing, including counselling about disclosure and referral for her partner(s) to return to the facility for testing.

    Behavioral: Counseling and referral for partner testing
    Counseling and refer participant's partner for facility based HIV testing

    Outcome Measures

    Primary Outcome Measures

    1. Partner HIV testing [3 months]

      proportion of index partners who report testing

    Secondary Outcome Measures

    1. Positivity [3 months]

      Proportion of male partners tested who test HIV+

    2. ART initiation [6 months]

      Proportion of male partners tested who initiate ART

    3. Viral suppression [6 months]

      Proportion of male partners and index partners who achieve viral suppression

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Adult female 18+ years old

    2. confirmed HIV-positive or on ART

    3. confirmed to currently have a male partner and are sexually active

    4. male partner is of HIV- or unknown status

    5. confirmed to have a cell phone that can read and respond to SMS/WhatsApp messages

    6. confirmed to be able to consent to study participation (no language constraints or psychological issues that would make it difficult to consent to participate in the study)

    Exclusion Criteria:

    Failure to meet all of inclusion criteria

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Health Clinics Nkangala Mpumalanga South Africa

    Sponsors and Collaborators

    • University of California, Los Angeles
    • Emory University
    • BroadReach Healthcare
    • USAID, South Africa
    • South African Department of Health, Mpumalanga Province

    Investigators

    • Principal Investigator: Kristin Wall, PhD, Emory University
    • Study Director: Kathryn Dovel, PhD, University of California, Los Angeles
    • Study Director: Dhirisha Naidoo, BroadReach Healthcare

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dvora Joseph Davey, PhD, MPH, Principal Investigator, University of California, Los Angeles
    ClinicalTrials.gov Identifier:
    NCT05074251
    Other Study ID Numbers:
    • BRHIVSTSA1
    First Posted:
    Oct 12, 2021
    Last Update Posted:
    Oct 19, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dvora Joseph Davey, PhD, MPH, Principal Investigator, University of California, Los Angeles
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 19, 2021